← Back to News & Events

Neon Therapeutics Expands Board of Directors with Leading Experts in Cancer Drug Discovery and Corporate Finance

Cambridge, Mass., December 12, 2017 – Neon Therapeutics, a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the expansion of the company’s Board of Directors with the addition of leading experts in translational cancer drug discovery and corporate finance.

Julian Adams, Ph.D., an accomplished scientist with a successful track record of drug discovery and development, and Meryl Zausner, former chief financial and administrative officer of Novartis, and will help to guide the company’s efforts to advance multiple immuno-oncology product candidates through research and development to patients.

“We are excited to add Meryl and Julian to our board, and look forward to the contributions they will make in the years ahead,” said Hugh O’Dowd, chief executive officer at Neon Therapeutics. “Their expertise and insight will be invaluable assets to Neon as we advance our next-generation immunotherapies through the clinic.”

Dr. Adams is a renowned scientist known for his success developing high impact therapies for cancer and HIV. Dr. Adams played a pivotal role in the development of multiple products to reach the market, including Viramune® (nevirapine) for HIV, and Velcade® (bortezomib), a proteasome inhibitor that revolutionized treatment of multiple myeloma. Dr. Adams has received numerous awards for his work including the 2012 Warren Alpert Foundation Prize, the 2012 C. Chester Stock Award Lectureship from Memorial Sloan-Kettering Cancer Center and the 2001 Ribbon of Hope Award from the International Myeloma Foundation. Dr. Adams currently serves as chairman and chief executive officer of Gamida Cell.

Ms. Zausner has more than 35 years of experience developing and launching innovative business units in the pharmaceutical and consumer product industry. Previously, Ms. Zausner served as chief financial and administrative officer of Novartis Pharmaceuticals Inc. in the US, and a member of the Pharmaceutical Executive Committee and Global Finance Leadership Team. In her time with Novartis Pharmaceuticals Inc., she was instrumental in the launch of the Oncology Business Unit, as well as the company’s shared services organization. Ms. Zausner was a member of the Novartis Global Oncology leadership team, and played a key role in developing and commercializing blockbuster therapies including Gleevec® (imatinib). Ms. Zausner currently is a board member and chair of the audit committee of the Multiple Myeloma Research Foundation, and board member of Dierdre’s House, an advocacy center for children who are victims of abuse or neglect.

About Neon Therapeutics

Neon Therapeutics is a clinical-stage immuno-oncology company leading in the field of neoantigen-targeted therapies and dedicated to transforming the treatment of each patient’s cancer by directing the immune system towards neoantigens. We have pioneered a proprietary neoantigen platform to develop neoantigen-targeted therapies using two distinct approaches. In NEON / ONE, these neoantigens are specific to each individual. In NEON / SELECT, these neoantigens are shared across subsets of patients and tumor types. Our most advanced product candidate is NEO‑PV‑01, a personal neoantigen vaccine, that is currently being evaluated in a Phase 1b open‑label clinical trial for patients with metastatic melanoma, non‑small cell lung cancer or bladder cancer.

For more information, please visit www.neontherapeutics.com.

Media Contact:
Dan Quinn, Ten Bridge Communications